46 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs https://www.zacks.com/stock/news/2247400/pharma-stock-roundup-abbv-nvo-s-new-m-as-fda-nod-to-jnj-mrk-pah-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2247400 Mar 28, 2024 - While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.
Bull Market Buys: 3 Dividend Stocks to Own for the Long Run https://www.fool.com/investing/2024/03/28/bull-market-buys-3-dividend-stocks-to-own-for-the/?source=iedfolrf0000001 Mar 28, 2024 - Invest in stability, dividends, and growth with these three accomplished real estate operators.
Astrazeneca (AZN) Rises As Market Takes a Dip: Key Facts https://www.zacks.com/stock/news/2246316/astrazeneca-azn-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2246316 Mar 26, 2024 - In the most recent trading session, Astrazeneca (AZN) closed at $66.33, indicating a +0.71% shift from the previous trading day.
AstraZeneca's (AZN) Ultomiris Gets FDA Nod for New Indication https://www.zacks.com/stock/news/2246063/astrazeneca-s-azn-ultomiris-gets-fda-nod-for-new-indication?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2246063 Mar 26, 2024 - FDA approves AstraZeneca's (AZN) Ultomiris for AQP4 Ab+ NMOSD, making it the first and only long-acting C5 complement inhibitor approved for this rare neurological disease.
Pharma Stock Roundup: AZN to Buy FUSN, PFE to Sell Stake in HLN & Other Updates https://www.zacks.com/stock/news/2245062/pharma-stock-roundup-azn-to-buy-fusn-pfe-to-sell-stake-in-hln-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2245062 Mar 22, 2024 - AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
Merck's (MRK) Keytruda-Lynparza Combo Fails 2nd Lung Cancer Study https://www.zacks.com/stock/news/2244951/merck-s-mrk-keytruda-lynparza-combo-fails-2nd-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244951 Mar 22, 2024 - Merck's attempt to use the Keytruda-Lynparza combination in certain non-small cell lung cancer patients has come up short with a second pivotal study failure.
GSK Follows Rivals, to Cap Out-of-Pocket Inhaler Cost in US https://www.zacks.com/stock/news/2244405/gsk-follows-rivals-to-cap-out-of-pocket-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2244405 Mar 21, 2024 - GSK plc (GSK) plans to lower the prices of its entire inhaled respiratory products to $35 per month in the United States. The company intends to start this in 2025.
AstraZeneca (AZN) to Buy Fusion Pharmaceuticals for $2.4B https://www.zacks.com/stock/news/2243580/astrazeneca-azn-to-buy-fusion-pharmaceuticals-for-2-4b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243580 Mar 20, 2024 - AstraZeneca (AZN) has offered to acquire Fusion for $21.00 per share in cash plus a contingent value (CV) payment of $3.00 per share.
AstraZeneca (AZN) Follows Boehringer, to Cap Inhaler Cost in US https://www.zacks.com/stock/news/2243035/astrazeneca-azn-follows-boehringer-to-cap-inhaler-cost-in-us?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2243035 Mar 19, 2024 - AstraZeneca (AZN) plans to lower the prices of its inhaled respiratory products to $35 per month in the United States. However, the company intends to start this in June 2024.
Pharma Stock Roundup: AZN's New Acquisition, FDA Updates for NVO & LLY and More https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azn-s-new-acquisition-fda-updates-for-nvo-lly-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2241296 Mar 15, 2024 - AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.

Pages: 12345

Page 1>